预约演示

Click Therapeutics picks up Better's app assets in diabetes, obesity

2024-05-22

并购

Click Therapeutics said it plans to tailor Better's AspyreRx app for Type 2 diabetes, cleared by the FDA last year, to also address obesity and GLP-1 medication management.

Click Therapeuticsper Click Therapeutics will increase its digital reType 2 diabetesg assets from theFDAcently defunct Better Therapobesity whicGLP-1an winding down its operations in March.

The purchase aims to jClick Therapeuticswork in obesity, diabetes and chronic cardiometabolic disease. Acquisitions froBetter Therapeuticso include AspyreRx, which received a de novo clearance from the FDA last year as the first digital therapeutic for Type 2 diabetes.

Click also picked up BT-004, a bClickhrough-desiobesityapdiabetesas bechronic cardiometabolic diseasefunction-associated steatohepatitis, also known as MASH, as well as BT-003 and BT-002, which target hFDA cholesterol and high blood pressure, respectiveType 2 diabetes

“There is immense potBT-004 in the cardiometabolic space for next-generation ‘smart’ themetabolic dysfunction-associated steatohepatitis capabilities,” Rich DeNunzio, ClBT-003chiefBT-002rcial officer, said in a statement.

However, Click isn’t heading to app stores just yet. The company said it does not plan to push AspyreRx in its current form—it will first modify the software to work better within Click’s own artificial-intelligence-enabled platform as well as connect it with the company’s previous in-house efforts to develop an obesity app known as CT-181.

By tailoring the diabetes-focused AspyreRx to also address obesity, Click believes that will put it on better footing to address a rapidly growing sector that has come to be dominated by GLP-1 medications—including today’s injectables and future oral drugs—by offering approaches in smart dosing, side effect managobesitynd behavioral CT-181t.

“Click can immedidiabetesrengthen AspyreRx by combining theobesity engagement technology from our platform with Better’s therapeutic core,” said Click’s chief technology officer, Han Chiu. “This allows us to efficiently deliver on the added clinical promise needed to support drug-software combination products with enhanced labels.”

The financial terms of the deal were not disclosed. The new additions will join Click’s previous work in smoking cessation, with its Clickotine app, as well as its recently cleared collaboration with Otsuka in major depressive disorder, Rejoyn. Click has also been working with Boehringer Ingelheim on apps for schizophrenia, as well as developing in-house programs for multiple sclerosis and migraine headaches, among other areas.

“The current one-size-fits-all approach to obesity management can be improved wiClicknovative digital therapeutics that tailor treatments to individual needs, leading to improved patient outcomes and the opportmajor depressive disorderen contracClickmodels with payers,” DeNunziBoehringer Ingelheimating with phschizophrenia providers and patients to layer these capabilmultiple sclerosisest dmigraine headachesform obesity care and enable our partners to succeed in what is soon to be a highly competitive market.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构